Anti-CD38 nanobodies as theranostic agents for multiple myeloma

被引：0
|
作者：
Duray, Elodie [1 ]
Lejeune, Margaux [1 ]
Dumoulin, Mireille [1 ]
D'Huyvetter, Matthias [2 ]
Caers, Jo [3 ]
机构：
[1] ULiege, Liege, Belgium
[2] Vrije Univ Brussel, Brussels, Belgium
[3] CHU Liege, Liege, Belgium
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2021年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OAB-044
引用
收藏
页码：S28 / S28
页数：1
相关论文
共 50 条
  • [31] CLINICAL OUTCOMES ASSOCIATED WITH ANTI-CD38 RETREATMENT IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: A REVIEW OF THE LITERATURE
    McNamara, S.
    Chorazy, J.
    Pandey, A.
    Bitetti, J.
    Boytsov, N.
    Purser, M.
    Iheanacho, I.
    VALUE IN HEALTH, 2024, 27 (06) : S31 - S31
  • [32] Clinical outcomes of retreatment with daratumumab-based regimens in anti-CD38 refractory multiple myeloma
    Tan, Carlyn Rose Co
    Rueda, Colin
    Shekarkhand, Tala
    Derkach, Andriy
    Korde, Neha
    Maclachlan, Kylee
    Hultcrantz, Malin
    Hassoun, Hani
    Mailankody, Sham
    Shah, Urvi A.
    Rajeeve, Sridevi
    Lahoud, Oscar Boutros
    Shah, Gunjan L.
    Scordo, Michael
    Chung, David J.
    Landau, Heather Jolie
    Giralt, Sergio
    Usmani, Saad Zafar
    Lesokhin, Alexander M.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [33] Treatment of Multiple Myeloma in Patients Refractory to Daratumumab/Anti-CD38 Monoclonal Antibodies: A Systematic Review
    Tan, Chia Jie
    Kacerek, Dylan
    Kampirapawong, Nattawara
    Godara, Amandeep
    Chaiyakunapruk, Nathorn
    CANCER MEDICINE, 2025, 14 (05):
  • [34] Genomic and Immune Determinants of Resistance to Anti-CD38 MoAb Based Therapy in Relapsed Multiple Myeloma
    Ziccheddu, Bachisio
    Giannotta, Claudia
    D'Agostino, Mattia
    Bertuglia, Giuseppe
    Saraci, Elona
    Oliva, Stefania
    Diamond, Benjamin
    Bolli, Niccolo
    Corradini, Paolo
    Coffey, David
    Landgren, Ola
    Bruno, Benedetto
    Boccadoro, Mario
    Massaia, Massimo
    Maura, Francesco
    Larocca, Alessandra
    BLOOD, 2023, 142
  • [35] Effects of Soluble and MicrovesicleBound Therapeutic Anti-CD38 Antibodies on Immune Effector Cells in Multiple Myeloma
    Oses, Lucrecia
    Brulc, Erika
    Carretero, Marcelina
    Nucifora, Elsa
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S418 - S418
  • [36] Determinants of Response to Anti-CD38 and Bispecific Combination Therapy in Patients with Relapsed/Refractory Multiple Myeloma
    Aleman, Adolfo
    Zajdman, Ariel Kogan
    Mouhieddine, Tarek
    Upadhyaya, Bhaskar
    Van Oekelen, Oliver
    Lagana, Alessandro
    Grossman, Leah
    Thibaud, Santiago
    Sanchez, Larysa
    Richard, Shambavi
    Rossi, Adriana
    Richter, Joshua
    Cho, Hearn Jay
    Rodriguez-Valdes, Cesar
    Chari, Ajai
    Parekh, Samir
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S41 - S41
  • [37] Minimal Residual Disease Significance in Multiple Myeloma Patients Treated with Anti-CD38 Monoclonal Antibodies
    Caroni, Federico
    Sammartano, Vincenzo
    Pacelli, Paola
    Sicuranza, Anna
    Malchiodi, Margherita
    Dragomir, Andreea
    Ciofini, Sara
    Raspadori, Donatella
    Bocchia, Monica
    Gozzetti, Alessandro
    PHARMACEUTICALS, 2025, 18 (02)
  • [38] COST OF ANTI-CD38 MONOCLONAL ANTIBODIES IN COMBINATION WITH CARFILZOMIB AND DEXAMETHASONE FOR RELAPSED REFRACTORY MULTIPLE MYELOMA
    Lin, P.
    Petitjean, A.
    Drea, E.
    Lin, F.
    VALUE IN HEALTH, 2024, 27 (06) : S148 - S148
  • [39] High response rates with IMiD retreatment post anti-CD38 exposure in patients with Multiple Myeloma
    Ntanasis-Stathopoulos, Ioannis
    Gavriatopoulou, Maria
    Malandrakis, Panagiotis
    Fotiou, Despina
    Migkou, Magdalini
    Kanellias, Nikolaos
    Eleutherakis-Papaiakovou, Evangelos
    Theodorakakou, Foteini
    Roussou, Maria
    Terpos, Evangelos
    Kastritis, Efstathios
    Dimopoulos, Meletios-Athanasios
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S154 - S154
  • [40] The effects of anti-CD38 monoclonal antibody and anti-HI antibody on pretransfusion testing in a patient with multiple myeloma
    Zhe Zhu
    Kairui Hong
    Yefang Ke
    Annals of Hematology, 2023, 102 : 1961 - 1962
12345